Patricia Martin, 58, former chief operating officer of Lilly’s diabetes division, will start her new job July 1, leading an organization that promotes and invests in the state’s life sciences sector.
Insurers said the idea could backfire, prompting hospitals that now give deeper discounts to try to raise their own negotiated prices to match what high earners are getting. Hospitals were skeptical of the move.
The federal regulations Trump is calling for would push forward a relatively simple idea: that patients should know how much hospitals charge for common procedures.
Recovery Centers of America, based in Pennsylvania, had been temporarily shut down in Massachusetts over concerns regarding patient care and safety. It is now planning to open its first Indiana treatment center.
Several diabetes and health care advocacy groups on Thursday announced a seven-figure fundraising campaign to help fund their fight against what they consider “skyrocketing” insulin prices.
In recent months, the drugmaker has won federal approval to sell a drug called Emgality for two conditions: migraine pain and cluster headaches.
The Louisville-based company expects to invest more than $52 million to launch its Indiana operations at the River Ridge Commerce Center in Jeffersonville.
The American Medical Association Opioid Task Force 2019 Progress Report shows Indiana's reduction in opioid prescriptions from 2013 to 2018 is two percentage points higher than the national average.
Array’s stock was already at a record before the deal announcement, following the company’s news last month of positive clinical trial results using Braftovi and Mektovi with Indianapolis-based Eli Lilly and Co.’s Erbitux.
Some of the biggest pharmaceutical companies, including Indianapolis-based Eli Lilly and Co., sued the Trump administration to try and block a rule that would force them to put the price of their drugs in television advertisements.
“Our central focus as a company is always to make lives better. … It’s a value that is core to every single employee who works here. So if we can have programs that reinforce that we are a company that is focused on making lives better, then we are doing something that connects to our mission and reminds our employees what really matters to us as a company.”
Across Indiana and the nation, hospitals are rolling out new programs to cut energy consumption and reduce their carbon footprints. In the process, they hope to save hundreds of thousands of dollars in the form of lower utility bills.
The trials, which will begin in 2020, are part of a sweeping, five-year, $42 million federal research program known as Implementing Genomics in Practice. The first trial will examine whether early access to patients’ genomic data can help with treatment of high blood pressure, hypertension and chronic kidney disease.
Indianapolis-based Anthem said its purchase of Beacon Health Options fits with its strategy of diversifying into providing health care services, including for patients with complex and chronic conditions.
It’s the second approved use for Emgality, which first won U.S. approval last fall to treat migraines. Analysts predict it could become a blockbuster.
A federal judge grilled an attorney for the state of Indiana on Monday over whether the Legislature had legitimate reasons for approving a law that would largely ban a second-trimester abortion procedure.
After one of its largest listed drug makers was found to have overstated its cash position by $4.3 billion, China is starting an audit of 77 major pharmaceutical companies.
The Indianapolis-based health system said the move will give patients more treatment options. It has opened five tiny hospitals in the last two years, and plans to open three more later this year.
To recognize the contribution, Eskenazi Health is changing the name of Midtown Community Mental Health to the Sandra Eskenazi Mental Health Center.
The medical field’s lofty dreams of unleashing the power of artificial intelligence to transform medicine have yet to materialize in a major way.
